ARTICLE | Product Development
What a pair of Phase II obesity results could mean for Altimmune, Pfizer
Will Altimmune’s pemvidutide be good enough to attract a partner? And will Pfizer go shopping after latest danuglipron data?
December 2, 2023 1:18 AM UTC
Updated on Dec 7, 2023 at 3:15 PM UTC
Neither of Friday’s Phase II obesity readouts, one from Altimmune and one from Pfizer, pointed to best-in-class potential. However, with efficacy similar to Wegovy, Altimmune could be positioned to partner. Pfizer, by contrast, has paused its twice-daily danuglipron program, which could send the pharma shopping for a new therapy.
After opening Friday up 82%, shares of Altimmune Inc. (NASDAQ:ALT) finished the day up 13%, giving the company a market cap of about $192 million, as investors digested results from the Phase II MOMENTUM trial of pemvidutide. ...